Healthcare & Insurance
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; March 7, 2021 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by
Sunday, March 07, 2021
Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections
High Lung Levels of Active Triphosphate Predicted with Oral AT-527 for COVID-19 Patients Data Supportive of AT-527 550 mg BID Dosing Regimen BOSTON, March 06, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today
Saturday, March 06, 2021
Allied Corp. Launches Strategic North American Public Relations and Marketing Campaign
KELOWNA, British Columbia, March 05, 2021 (GLOBE NEWSWIRE) -- Allied Corp. (the “Company” or “Allied”) (OTCQB: ALID) is pleased to announce that it has retained the services of IDR Marketing, Inc. to provide public relations strategies, brand awareness, financial and digital marketing
Saturday, March 06, 2021
Algernon Pharmaceuticals Announces Increase and Close of Private Placement
VANCOUVER, British Columbia, March 05, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has increased and completed its
Saturday, March 06, 2021
Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection
First and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19 T-Detect COVID correctly confirmed recent or prior COVID-19 infections 97.1% of the time from date of RT-PCR diagnosis with 100% specificity
Friday, March 05, 2021
Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021
DUBLIN, Ireland and CHICAGO, March 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both
Friday, March 05, 2021
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an
Friday, March 05, 2021
AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement
SAN JOSE, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that on March
Friday, March 05, 2021
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of 14,565 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective
Friday, March 05, 2021
DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference
Montrouge, France, March 5, 2021 DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief
Friday, March 05, 2021
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to two new employees with grant date of March 1, 2021, as
Friday, March 05, 2021
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 14,300 shares of G1’s common stock to two employees under the G1
Friday, March 05, 2021
Lowell Farms Inc. Emerges From Acquisition With an Eye Toward Dominance in California’s Cannabis Industry and Beyond
Formerly Indus Holdings, Inc., cannabis leader completes name change and lays out strategy for future successSALINAS, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a leading, vertically-integrated, California-focused cannabis company,
Friday, March 05, 2021
Vor Biopharma to Present at the Barclays Global Healthcare Conference
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the
Friday, March 05, 2021
Progressive Announces Quarterly Common Share Dividend
MAYFIELD VILLAGE, OHIO, March 05, 2021 (GLOBE NEWSWIRE) -- The Board of Directors of The Progressive Corporation (NYSE:PGR) today declared a $0.10 per common share dividend, payable April 15, 2021, to shareholders of record at the close of business on April 7, 2021 (ex-dividend date of April 6,
Friday, March 05, 2021
Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference
HAMPTON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company’s participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conference. The presentation for the virtual conference was prerecorded and will be accessible to
Friday, March 05, 2021
VÍS: Viðskipti fruminnherja
Sjá meðfylgjandi tilkynningar um viðskipti fruminnherja hjá Vátryggingafélagi Íslands: Attachments 21.03.05 Vidskipti-fruminnherja_ARÍ 21.03.05 Vidskipti-fruminnherja_AG 21.03.05
Friday, March 05, 2021
Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2021
Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2021. Article
Friday, March 05, 2021
EssilorLuxottica : Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2021
Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2021 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers) Charenton-le-Pont, France (March 5, 2021 - 6:00 pm) -
Friday, March 05, 2021
Major Shareholder Announcement
Not for release, publication or distribution in whole or in part, in, or into the United States.Not for release, publication or distribution, in whole or in part, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.
Friday, March 05, 2021
